Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 30, 2013 in Melanoma | 0 comments

In a nutshell

The present article evaluated the time interval and site of relapse (return of the cancer) as well as survival rates in stage III melanoma patients who were considered cured after treatment. 

Some background

Stage III melanoma is skin cancer that has spread to the nearby lymph nodes. Further classification (III A, III B and III C) is based on how many lymph nodes are positive for cancer and the thickness of the primary skin tumor. Treatment for stage III usually includes surgery to remove the melanoma and positive lymph nodes as well as postoperative (or "adjuvant") therapy with melanoma vaccines, interferon or radiation. Patients with no evidence of cancer after treatment still have a high risk for relapse. Therefore, careful follow up including regular doctor visits, imaging test (chest x-rays, CT scans) and blood tests are very important. Current guidelines recommend physical examinations every 3 to 6 months for the first 3 years and then every 4 to 12 months.

Methods & findings

This study included 340 patients diagnosed with AJCC stage III melanoma between 1992 and 2004 who relapsed after first being cured of the disease. Of these patients, 28% had stage III A, 46% had stage III B and 26% had stage III C melanoma. During follow up, patients were evaluated at 3 months intervals for the first 2 years, then every 6 months. Parameters measured were time to first relapse, the site where the cancer relapsed and also relapse-free survival (RFS) 5 years after treatment of the melanoma. RFS is defined as the length of time without any relapse.
The site of first relapse was local in 28% patients, in the nearby lymph nodes in 21% of patients and in distant organs (systemic) in 51% of patients. First relapses were detected by the patient or their family in 47% of patients and by their doctor or in imaging tests in 21% and 32% patients respectively. The RFS 5 years after treatment for stage IIIA, IIIB and IIIC was 63%, 32% and 11% respectively.

The bottom line

In summary, almost half of all melanoma relapses were detected by the patients themselves and most relapses were systemic. The study found better survival rates in younger patients who had no symptoms, who had local or nodal relapse (not systemic) and whose cancer was resectable (could be removed by surgery). 

The fine print

This study looks back at patients who have been treated in the past (retrospective study) rather than following the patients throughout their treatment and determining their outcomes (prospective study). Retrospective studies are considered to provide weak statistical evidence. Also, this group of patients came from a single melanoma treatment center. Future studies should include larger populations throughout the world for the data to be more representative for the general population.
 

What’s next?

Apart from the regular physical examination done by your doctor, you should self-examine yourself at least monthly. You should see your doctor if you find any new lump or change on your skin. You should also report any new symptoms (pain, cough, fatigue, loss of appetite) that do not go away.    

Published By :

Journal of clinical oncology

Date :

Jun 20, 2010

Original Title :

Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines

click here to get personalized updates